| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
This peptide targets integrin receptors, particularly alphavbeta3 and alphavbeta5 integrins, which are known to bind vitronectin. By mimicking the integrin-binding region of full-length vitronectin, the peptide can competitively inhibit or promote specific cell-matrix interactions, influencing downstream signaling pathways involved in cell adhesion, survival, and migration.
|
|---|---|
| ln Vitro |
In vitro, vitronectin (367-378) promotes or inhibits cell adhesion depending on the experimental setup. When immobilized on culture plates, it supports the attachment and spreading of various cell types, including endothelial cells, fibroblasts, and cancer cells, by engaging their vitronectin-specific integrins. This property makes it useful for studying integrin-mediated signaling and cell motility.
|
| ln Vivo |
Specific in vivo activity data for this fragment are limited. However, vitronectin-derived peptides are generally used to modulate cell adhesion and migration in animal models of wound healing and angiogenesis. By competing with endogenous vitronectin, the peptide can influence processes such as re-epithelialization, neovascularization, and tumor metastasis in mouse models.
|
| Enzyme Assay |
A direct binding assay is performed to study integrin-peptide interaction. Purified integrin proteins (e.g., alphavbeta3) are immobilized on an ELISA plate. Biotinylated vitronectin (367-378) is added at varying concentrations, and binding is detected using streptavidin-HRP. Alternatively, surface plasmon resonance (SPR) is used to calculate the binding affinity (Kd) by flowing the peptide over an integrin-coated sensor chip.
|
| Cell Assay |
A cell adhesion assay is the primary in vitro functional test. Multiwell plates are coated with vitronectin (367-378) or full-length vitronectin as a control. Cells (e.g., human dermal fibroblasts or endothelial cells) are seeded onto the coated plates and allowed to adhere for 30-60 minutes. Non-adherent cells are washed away, and adherent cells are stained with crystal violet or Calcein-AM, followed by quantification using a microplate reader.
|
| Animal Protocol |
In vivo protocols generally involve wound healing models. A mouse is anesthetized, and full-thickness excisional wounds are created on the dorsal skin. The vitronectin (367-378) peptide is applied topically or injected intradermally around the wound edge. Wound closure is monitored by digital imaging every 1-2 days for up to 14 days. At endpoint, wound tissues are harvested for histological analysis (e.g., H&E staining) to assess re-epithelialization and granulation tissue formation.
|
| ADME/Pharmacokinetics |
As a hydrophilic peptide (MW: 1667.92, sequence GKKQRFRHRNRKG), vitronectin (367-378) is poorly absorbed systemically when applied topically. It has a short half-life in circulation (minutes) due to rapid proteolytic degradation. It is soluble in water (100 mg/mL) and is typically stored as a powder at -20degC or -80degC to maintain stability.
|
| Toxicity/Toxicokinetics |
The peptide is generally regarded as safe for research applications at standard concentrations (e.g., 1-100 ug/mL in vitro). It does not exhibit direct cytotoxicity to cultured cells at these doses. For in vivo use, repeated topical or intradermal administration has not been reported to cause significant local or systemic toxicity beyond the intended effects on wound healing.
|
| References |
[1]. Burgos-Panadero R, et al. Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma. BMC Cancer. 2019;19(1):479. Published 2019 May 22.
|
| Additional Infomation |
The short sequence is GKKQRFRHRNRKG (Gly-Lys-Lys-Gln-Arg-Phe-Arg-His-Arg-Asn-Arg-Lys-Gly). It is often used in skin and cosmetic research to support investigations into dermal regeneration and anti-aging strategies. The parent protein, vitronectin, is also known as serum-spreading factor or S-protein. This peptide is strictly a research-grade tool and is not an approved therapeutic.
|
| Molecular Formula |
C70H122N32O16
|
|---|---|
| Molecular Weight |
1667.92249059677
|
| Exact Mass |
1666.971
|
| CAS # |
1217344-74-5
|
| PubChem CID |
168013074
|
| Appearance |
White to off-white solid powder
|
| LogP |
-12.2
|
| Hydrogen Bond Donor Count |
32
|
| Hydrogen Bond Acceptor Count |
25
|
| Rotatable Bond Count |
66
|
| Heavy Atom Count |
118
|
| Complexity |
3300
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CN
|
| InChi Key |
SAXSNZNBEWVSJE-LFOOZZFTSA-N
|
| InChi Code |
InChI=1S/C70H122N32O16/c71-25-7-4-16-41(56(108)90-37-55(106)107)93-59(111)44(19-10-28-86-67(77)78)98-66(118)51(34-53(76)104)102-62(114)47(22-13-31-89-70(83)84)97-65(117)50(33-40-36-85-38-91-40)101-61(113)46(21-12-30-88-69(81)82)96-64(116)49(32-39-14-2-1-3-15-39)100-60(112)45(20-11-29-87-68(79)80)95-63(115)48(23-24-52(75)103)99-58(110)43(18-6-9-27-73)94-57(109)42(17-5-8-26-72)92-54(105)35-74/h1-3,14-15,36,38,41-51H,4-13,16-35,37,71-74H2,(H2,75,103)(H2,76,104)(H,85,91)(H,90,108)(H,92,105)(H,93,111)(H,94,109)(H,95,115)(H,96,116)(H,97,117)(H,98,118)(H,99,110)(H,100,112)(H,101,113)(H,102,114)(H,106,107)(H4,77,78,86)(H4,79,80,87)(H4,81,82,88)(H4,83,84,89)/t41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-/m0/s1
|
| Chemical Name |
2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[(2-aminoacetyl)amino]hexanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (59.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (29.98 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5995 mL | 2.9977 mL | 5.9955 mL | |
| 5 mM | 0.1199 mL | 0.5995 mL | 1.1991 mL | |
| 10 mM | 0.0600 mL | 0.2998 mL | 0.5995 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
